Clinical Trials Logo

Clinical Trial Summary

Patients suffering from COVID-19 (Coronavirus Disease 2019) pneumonia are prone to bacterial and mycotic superinfection. According to existing evidence, the prevalence of superinfection is about 8% to 14% (95% CI 5-26%). However, the percentage of patients treated for superinfection is as high as 80%. There can be multiple reasons for this difference.

Clinical Trial Description

The inflammatory markers, such as C-reactive protein (CRP), procalcitonin (PCT), presepsin (PSP), interleukin-6 (IL-6) frequently used as diagnostic tools in COVID-19 (Coronavirus Disease 2019), are usually increased in these patients. This increase is a result of activation of systemic inflammatory cascade, part of COVID-19 pathophysiologic pathway. This can escalate to state known as COVID-19 associated hyperinflamation (COV-HI). In addition, current diagnostic tools for diagnosing HAP/VAP (hospital-acquired pneumonia and ventilator-associated pneumonia) are often limited in patients with COVID-19 pneumonia. The current method of choice for superinfection diagnosing is BAL (Bronchoalveolar Lavage). The COV-HI phenotype (COV-HI: CRP > 150 mg/L, or doubling within 24 h from greater than 50 mg/L, or ferritin concentration > 1500 ug/L) is associated with significantly worse course of illness and higher mortality rates. These inflammatory markers may be used preferentially as prognostication tools, not bacterial superinfection markers. The intention of this project is to investigate the role of currently used inflammatory biomarkers. Or eventually, to discover new parameters associated with superinfection proven by BAL. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04867161
Study type Observational
Source Brno University Hospital
Contact Jan Maláska
Phone +420532232009
Email [email protected]
Status Recruiting
Start date December 21, 2020
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Recruiting NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Active, not recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Not yet recruiting NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1
Recruiting NCT04845971 - Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia Phase 2
Recruiting NCT04346147 - Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 Phase 2
Completed NCT04381858 - Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04868864 - The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Trajectory Sub-study
Completed NCT04363736 - A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia Phase 2
Recruiting NCT04625036 - NO-mediated Vascular Function in Covid-19 Patient
Recruiting NCT04424901 - Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 Phase 2
Not yet recruiting NCT04370223 - Ozone Auto-hemotherapy for COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04398303 - ACT-20 in Patients With Severe COVID-19 Pneumonia Phase 1/Phase 2
Recruiting NCT04461925 - Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs Phase 1/Phase 2
Recruiting NCT04622826 - plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients Phase 2
Recruiting NCT04438980 - Glucocorticoids in COVID-19 (CORTIVID) Phase 3
Recruiting NCT04372186 - A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia Phase 3
Completed NCT04610554 - Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19
Recruiting NCT04361942 - Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV) Phase 2